INTRODUCTION
A key problem in the effective treatment of patients with cancer (both leukemia and solid tumors) is how to distinguish between tumor and normal cells. This largely explains why current cancer treatments are often ineffective. There have been remarkable advances in our understanding of the molecular biology of cancer, providing new mechanisms for selective tumor destruction (1) (2) (3) . The molecular characterization of tumor-specific chromosomal abnormalities has revealed that fusion proteins are involved in the majority of cancers (4) (5) (6) . These fusion proteins are encoded by chimaeric genes generated by the chromosomal rearrangement. These chimeric molecules represent ideal therapeutic tar-gets since they are unique to the disease state (they only exist in the tumor cells, not in the normal cells of the patient) (1) (2) (3) .
In the hematopoietic system, a well-characterized chromosomal rearrangement brings together the BCR and ABL genes in Philadelphia chromosome positive (Phl+) chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (Phl+-ALL) cells (7, (8) (9) (10) (11) (12) (13) (14) (15) (16) . Depending on the precise location of the translocation breakpoint within the BCR gene, BCR-ABL fusion proteins of either 210 kD (p210) or 190 kD (pI90) in size are produced, possessing deregulated ABL tyrosine kinase activity. The p210 and p190 BCR-ABL oncogenes contain identical ABL-derived sequences, but differ in the number of BCR-encoded amino acid residues (8, 10, 11, 13, (17) (18) (19) (20) . We have previously shown that the BCR-ABL oncogenes act by inhibiting apoptosis via a Bcl-2 pathway as a part of their oncogenic phenotype (21) . Inhibition of p190 expression in 126 Molecular Medicine, Volume 2, Number 1, January 1996 the Ba/F3+pI90 mouse hematopoetic cell line reverted this phenotype and cells died by apoptosis (3, 21) . This suggested that inhibition of p190 expression could similarly inhibit the leukemic phenotype of human Phl+ -ALL cells leading to a new therapeutic approach in this disease.
A major challenge is to deliver an anti-tumor drug into every tumor cell. If this is not achieved, any malignant cell that remains unaffected will emerge as a resistant clone. Several experiments have demonstrated the feasibility of using antisense oligonucleotides (1,2) to produce sequence-specific inhibition of gene expression. However, these oligonucleotides are unable to enter the majority of cell types with high efficiency, so that some type of delivery system is essential (22) . In the present study we have employed a novel strategy to introduce specific antitumor drugs into tumor cells. It uses retroviral vectors encoding both antisense sequences specific for the BCR-ABLP'90 fusion junction and a truncated human CD5 protein encoding only the extracellular and transmembrane domains and therefore defective in signal transduction. This marker allows the selection of all infected cells.
MATERIALS AND METHODS

Plasmid Construction
The MFGA190CD5 and the MFGS190CD5 retroviral vectors are based on a simplified MFG retroviral vector, which does not contain a gene for a dominant selectable marker (23) . The sequences subcloned into the MFG vector (23) were as follows: 61 nucleotides spanning the BCR-ABL junction either in antisense (MFGA190CD5 vector) or sense orientations (MFGS 1 90CD 5 vector); the picornaviral internal ribosome-entry site (IRES) sequence (24) ; and a 1218-bp sequence from the human CD5 cDNA encoding the complete extracytoplasmic region. CD5 DNA fragments were generated by reverse transcriptase polymerase chain reaction (PCR) using primers that included initiation and termination codons. The authenticity of the constructs generated was confirmed by DNA sequencing and revealed neither PCR errors nor cloning artifacts. The proviral structure of these vectors is shown in Fig. IA (Table 1 and Fig. 2A, top panels) . CD5 expression provided a marker for cells infected with the retrovirus. Following IL-3 removal, the Ba/F3+pl9O cells infected with retrovirus carrying antisense BCR-ABLP'90 sequences died, as determined by lack of CD 5-positive cells (Table 1 and Fig. 2A, bottom The data suggest a possible strategy treating Philadelphia positive ALL or CML. The strategy makes use of retrovirus which enables dual expression of both a selectable marker (truncated CD5) and a tumor-specific agent (antisense oligonucleotides specific for tumor-associated fusion proteins). In this way, following ex vivo targeting, only cells expressing both a tumor-specific agent and a selectable cell surface marker would be used for bone marrow reconstitution in a These results suggest a new approach for in vitro gene therapy of hematopoietic cancer: autografting patients with bone marrow cells infected in vitro with the retrovirus expressing sequences targeted specifically against the tumor-associated fusion junctions and a selectable marker, followed by nontoxic selection, ensures that all reinfused stem cells will contain integrated antisense sequences. This strategy would thus make it possible to restore cancer-negative hematopoesis in patients.
